natgillin/translations-raw huggingface dataset:
Symptoms of a local or systemic infection possibly related to Imlygic are anticipated to be similar to symptoms caused by wild-type HSV-1 infections. 
Simptomi lokalne ali sistemske okužbe, ki bi lahko bila povezana z zdravilom Imlygic, so predvidoma podobni simptomom, ki jih povzročajo okužbe z divjim tipom HSV-1.
Patients who develop herpetic infections should be advised to follow standard hygienic practices to prevent viral transmission. 
Bolnikom, ki se jim pojavi herpetična okužba, je treba naročiti, naj upoštevajo standardne higienske ukrepe za preprečitev prenosa virusa.
Imlygic may increase the risk of impaired healing in patients with underlying risk factors (e.g. previous radiation at the injection site, or lesions in poorly vascularised areas). 
Zdravilo Imlygic lahko poveča tveganje za slabše celjenje pri bolnikih z osnovnimi dejavniki tveganja (npr. s predhodnim obsevanjem mesta injiciranja ali s spremembami v slabo prekrvljenih predelih).
Dose concentrations 
Koncentracija odmerkov
The mean (SD) treatment duration for the intent-to-treat (ITT) population was 15.76 weeks (15.79) in the GM-CSF arm and 26.83 weeks (18.39) in the Imlygic arm. 
Povprečno trajanje zdravljenja (standardni odklon) v populaciji z-namenom-zdravljenja je bilo v skupini z GM-CSF 15,76 tedna (15,79) in v skupini z zdravilom Imlygic 26,83 tedna (18,39).
Excipient with known effect 
Pomožni snovi z znanim učinkom
• Trained HCPs and support personnel regarding safe and appropriate storage, handling, and administration of IMLYGIC, and clinical follow-up for patients treated with IMLYGIC; 
• Zdravstveni delavci in podporno osebje morajo biti usposobljeni v zvezi z varnim in ustreznim shranjevanjem, ravnanjem in dajanjem zdravila IMLYGIC ter nadaljnjim kliničnim spremljanjem bolnikov, zdravljenih z zdravilom IMLYGIC.
To minimise the risk of viral transmission, patients should keep their injection site covered for at least 8 days from the last treatment or longer if the injection site is weeping or oozing. 
Da bi se zmanjšalo tveganje za prenos virusa, naj imajo bolniki mesto injiciranja pokrito vsaj 8 dni po zadnjem zdravljenju ali dlje, če je na mestu injiciranja opazno izcejanje ali mezenje.
Therefore, its pharmacokinetics and biodistribution are driven by the site of intralesional injection, tumour-selective replication, and release from tumour tissue. 
Zato sta njegova farmakokinetika in bioporazdelitev odvisna od mesta intralezijskega injiciranja, tumorsko selektivnega razmnoževanja in sproščanja iz tumorskega tkiva.
If a pregnant woman has an infection with wild type HSV-1 (primary or reactivation), there is potential for the virus to cross the placental barrier, and also a risk of transmission during birth due to viral shedding. 
Če ima nosečnica okužbo z divjim tipom HSV-1 (primarno ali reaktivirano), obstaja možnost prehoda virusa skozi placentno bariero; zaradi izločanja novih virusov po njihovem razmnoževanju obstaja tudi možnost prenosa med porodom.
No adjustment of the dose is required in patients ≥ 65 years old (see section 5.1). 
Bolnikom, starim ≥ 65 let, odmerka ni treba prilagoditi (glejte poglavje 5.1).
Injectable anaesthetic may be injected around the periphery of the lesion but should not be injected directly into the lesion. 
Injektabilni anestetik lahko injicirate okrog periferije spremembe, ne smete pa ga injicirati neposredno vanjo.
Name and address of the manufacturer of the biological active substance BioVex Inc. - Subsidiary of Amgen, Inc. 
Ime in naslov izdelovalca biološke učinkovine BioVex Inc. - Subsidiary of Amgen, Inc. 34 Commerce Way
While there are no clinical data to date on talimogene laherparepvec infections in pregnant women, there could be a risk to the foetus or neonate if talimogene laherparepvec were to act in the same manner. 
Ker kliničnih podatkov o okužbah s talimogenom laherparepvekom pri nosečnicah do zdaj ni, bi lahko obstajalo tveganje za plod ali novorojenčke, če bi talimogen laherparepvek deloval enako.
Ensure that your close contacts who are pregnant or who have a weakened immune system do not touch injection sites, used dressings and cleaning materials. 
Poskrbite, da se osebe, ki so z vami v tesnem stiku in so noseče ali imajo oslabljen imunski sistem, ne bodo dotikale vaših mest injiciranja, uporabljenih povojev in materiala za čiščenje.
Unused medicine must be disposed of in compliance with the institutional guidelines for genetically modified organisms or biohazardous waste, as appropriate. 
Neporabljeno zdravilo je treba zavreči v skladu s smernicami ustanove za genetsko spremenjene organizme ali biološko nevarne odpadke, kot je primerno.
Of the responders, 42 (54%) experienced a ≥ 25% increase in overall size of existing lesion(s) and/or developed a new lesion(s) prior to ultimately achieving a response. 
Od bolnikov, ki so se odzvali, se je pri 42 (54 %) pojavilo ≥ 25 % povečanje skupne velikosti obstoječe spremembe/obstoječih sprememb in/ali se jim je pojavila nova sprememba/nove spremembe, preden so končno dosegli odziv.
Talimogene laherparepvec was also quantified in selected patient samples in clinical studies using viral infectivity assays at the injection sites and in some cases of potential herpetic lesions. 
Prav tako so talimogen laherparepvek kvantificirali v izbranih vzorcih bolnikov v kliničnih študijah z uporabo preizkusov virusne infektivnosti na mestih injiciranja in v nekaterih primerih možnih herpetičnih sprememb.
Kaplan-Meier estimate of overall survival by randomised treatment arm for disease stage IIIB/IIIC/ stage IVM1a (exploratory subgroup analysis) 
Slika 5: Kaplan-Meierjeva ocena celokupnega preživetja po randomizirani terapevtski skupini in stadiju bolezni IIIB/IIIC/ stadiju IVM1a (analiza eksplorativnih podskupin)
Unused medicine must be disposed of in compliance with the institutional guidelines for genetically modified organisms or biohazardous waste. 
Neporabljeno zdravilo je treba zavreči v skladu s smernicami ustanove za genetsko spremenjene organizme ali biološko nevarne odpadke.
• Determine injection volume for each lesion using table 2 above. 
• Za vsako spremembo določite količino za injiciranje na podlagi zgornje preglednice 2.
Because wild-type HSV-1 does not integrate into the host genome, the risk of insertional mutagenesis with talimogene laherparepvec is negligible. 
Divji tip HSV-1 se ne integrira v genom gostitelja, zato je tveganje za insercijsko mutagenost s talimogenom laherparepvekom zanemarljivo.
Talimogene laherparepvec is a genetically modified and replication-competent HSV-1 virus. 
Talimogen laherparepvek je gensko spremenjen in za razmnoževanje sposoben virus HSV-1.
This may impair your ability to drive or operate machinery. 
To lahko poslabša vašo sposobnost upravljanja vozil in strojev.
Wipe the exterior of occlusive dressing with an alcohol wipe. 
Zunanjost okluzivnega povoja obrišite z alkoholnim zložencem.
• Avoid direct contact with your body fluids or injection sites. 
• se izognejo neposrednemu stiku z vašimi telesnimi tekočinami in mesti injiciranja.
• Tissue swelling (peripheral oedema) 
• otekanje tkiva (periferni edemi),
• Patient alert card 
• Opozorilno kartico za bolnika
• Thawed Imlygic is stable when stored at temperatures of 2°C up to 25°C protected from light in its original vial, in a syringe, or in the original vial followed by a syringe. 
• Odtajano zdravilo Imlygic je stabilno, kadar ga shranjujete pri temperaturi od 2°C do 25°C, zaščiteno pred svetlobo v originalni viali, v injekcijski brizgi, ali v originalni viali in nato v injekcijski brizgi.
Whereas anti-viral immune responses defend normal cells following infection by talimogene laherparepvec, tumours have been shown to be susceptible to injury and cell death from ICP34.5deficient HSV-1 viruses, including talimogene laherparepvec. 
Medtem ko protivirusni imunski odzivi po okužbi s talimogenom laherparepvekom branijo normalne celice, so tumorji dokazano občutljivi za poškodbo in celično smrt zaradi virusov HSV-1 brez ICP34.5, vključno s talimogenom laherparepvekom.
Do not exceed the storage times specified in table 1 and table 2. 
Ne prekoračite časov shranjevanja, opisanih v preglednici 1 in preglednici 2.
Imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease (see sections 4.4 and 5.1). 
Zdravilo Imlygic je indicirano za zdravljenje odraslih bolnikov z inoperabilnim melanomom, ki imajo regionalne ali oddaljene zasevke (stopenj IIIB, IIIC in IVM1a) in nimajo kostne, možganske, pljučne ali druge visceralne bolezni (glejte poglavji 4.4 in 5.1).
Censor indicated by Vertical Bar I. 
Krnjenje je označeno z navpičnimi črticami I.
There is no clinical experience with overdose with Imlygic. 
Kliničnih izkušenj s prevelikim odmerjanjem zdravila Imlygic ni.
• Adequately trained and experienced HCPs in order to minimise the risk of occurrence of specified adverse drug reactions in patients, HCPs, and close contacts of the patients; 
• Zdravstveni delavci morajo biti ustrezno usposobljeni in izkušeni, da bi zmanjšali tveganje za pojav določenih neželenih reakcij zdravila pri bolnikih, zdravstvenih delavcih in osebah, ki so v tesnem stiku z bolnikom.
• Apply pressure to the injection site with a sterile gauze for at least 30 seconds. 
• Na mesto injiciranja vsaj 30 sekund pritiskajte s sterilno gazo.
No clinical studies have been performed to evaluate the effects of talimogene laherparepvec on fertility (see section 5.3). 
Kliničnih študij za oceno vplivov talimogena laherparepveka na plodnost niso izvedli (glejte poglavje 5.3).
In the event of a suspected overdose or inadvertent intravenous administration, the patient should be treated symptomatically, e.g. with acyclovir or other anti-viral agents (see section 4.4) and supportive measures instituted as required. 
V primeru suma na preveliko odmerjanje ali nenamerne intravenske uporabe je treba bolnika zdraviti simptomatsko, npr. z aciklovirjem ali drugimi protivirusnimi zdravili (glejte poglavje 4.4) ter uporabiti podporne ukrepe, kot je potrebno.
It is unknown whether talimogene laherparepvec is transferred into human milk. 
Ni znano, ali se talimogen laherparepvek izloča v materino mleko.
If you miss an appointment, ask your healthcare professional when to schedule your next dose. 
Če pregled izpustite, prosite zdravstvenega delavca za nov datum za naslednji odmerek.
• 106 (1 million) PFU/mL - For initial dose only. 
• 106 (1 milijon) PFU/ml - samo za začetni odmerek.
To allow for delayed immune-mediated anti-tumour effects to occur, patients were treated for a minimum of 6 months or until there were no longer any injectable lesions. 
Da bi omogočili pojav zakasnjenih imunsko pogojenih protitumorskih učinkov, so bolnike zdravili vsaj 6 mesecev, ali dokler niso več imeli nobene spremembe, v katero bi bilo mogoče injicirati.
As a precautionary measure, it is preferable to avoid the use of talimogene laherparepvec during pregnancy. 
Iz previdnostnih razlogov se je med nosečnostjo uporabi talimogena laherparepveka bolje izogibati.
This medicinal product contains approximately 30 mg sodium per 4 mL dose, equivalent to 1.5% of the WHO recommended maximum daily intake of 2 g sodium for an adult. 
To zdravilo vsebuje približno 30 mg natrija na 4 ml odmerek, kar ustreza 1,5 % dnevnega vnosa 2 g natrija za odraslo osebo, ki ga priporoča SZO.
Your healthcare professional will decide which tumour(s) to inject and may not inject every tumour. 
Zdravstveni delavec bo presodil, v kateri tumor je treba injicirati zdravilo in ga morda ne bo injiciral v vsak tumor.
As talimogene laherparepvec is injected and replicates intratumourally, bioavailability and systemic concentration of talimogene laherparepvec are not predictive of drug substance activity and therefore have not been evaluated. 
Ker se talimogen laherparepvek injicira in razmnožuje v tumorju, biološka uporabnost in sistemska koncentracija talimogena laherparepveka ne napovedujeta aktivnosti učinkovine in ju zato niso ovrednotili.
Caution should be used when injecting lesions close to major airways. 
Potrebna je previdnost pri injiciranju v spremembe, ki so blizu večjih dihalnih poti.
Herpes infection 
Okužba s herpesom
The genotoxic potential of talimogene laherparepvec has not been evaluated in long-term animal or human studies. 
Genotoksičnosti talimogena laherparepveka niso ocenili v dolgoročnih študijah na živalih ali pri človeku.
• In the event of an accidental occupational exposure to Imlygic (e.g. through a splash to the eyes or mucous membranes) during preparation or administration, flush with clean water for at least 15 minutes. 
• V primeru nenamerne poklicne izpostavljenosti zdravilu Imlygic (npr. zaradi oškropitve oči ali sluznic) med pripravo ali dajanjem zdravila vsaj 15 minut izpirajte s čisto vodo.
Based on animal data, patients who are severely immunocompromised may be at an increased risk of disseminated herpetic infection and should not be treated with Imlygic (see sections 4.3 and 5.3). 
Podatki na živalih kažejo, da imajo lahko zelo imunokompromitirani bolniki večje tveganje za diseminirano herpetično okužbo in ne smejo prejemati zdravila Imlygic (glejte poglavji 4.3 in 5.3).
Accidental spread of Imlygic to yourself and others 
Nenamerno prenašanje zdravila Imlygic nase in na druge
When you are being treated with Imlygic you may experience symptoms such as dizziness or confusion. 
Med zdravljenjem z zdravilom Imlygic se vam lahko pojavijo simptomi, kot sta omotica ali zmedenost.
8 hours 
8 ur
Across studies, fatal disseminated viral infection was observed in 14% of nude mice following treatment with talimogene laherparepvec at doses that are 10 to 100-fold higher than those that result in 100% lethality with wild-type HSV-1. 
V študijah so smrtne diseminirane virusne okužbe opažali pri 14 % golih miši po zdravljenju s talimogenom laherparepvekom v odmerkih, od 10- do 100-krat večjih od odmerkov, ki povzročijo 100 % smrtnost z divjim tipom HSV-1.
The safety and efficacy of Imlygic monotherapy compared with subcutaneously administered GM-CSF were evaluated in a phase 3, multinational, open-label, and randomised clinical study of patients with stage IIIB, IIIC, and IV melanoma that was not considered to be surgically resectable. 
Varnost in učinkovitost monoterapije z zdravilom Imlygic v primerjavi s subkutano uporabljenim GM-CSF so ocenili v mednarodni, odprti, randomizirani klinični študiji 3. faze pri bolnikih z melanomom stopenj IIIB, IIIC in IV, ki je bil ocenjen kot inoperabilen.
Negligible amounts (< 0.001% of maternal blood levels) of talimogene laherparepvec DNA were found in foetal blood. 
V krvi plodov so našli zanemarljivo količino (< 0,001 % koncentracije v materini krvi) DNA talimogena laherparepveka.
• First inject any new lesions (lesions that may have developed since initial treatment). 
• Najprej injicirajte v morebitne nove spremembe (spremembe, ki so se morda pojavile od začetnega zdravljenja).
As long as there are injectable lesion(s) remaining, Imlygic should be continued for at least 6 months unless the physician considers that the patient is not benefitting from Imlygic treatment or that other treatment is required. 
Dokler obstajajo spremembe, v katere je mogoče injicirati, je treba uporabo zdravila Imlygic nadaljevati vsaj 6 mesecev, razen če zdravnik presodi, da bolniku zdravljenje z zdravilom Imlygic ne koristi ali da je potrebno drugo zdravljenje.
The most commonly reported adverse reactions (≥ 25%) in Imlygic-treated patients were fatigue (50.3%), chills (48.6%), pyrexia (42.8%), nausea (35.6%), influenza-like illness (30.5%), and injection site pain (27.7%). 
Med bolniki, ki so prejemali zdravilo Imlygic, so najpogosteje (≥ 25 %) poročali o neželenih učinkih utrujenost (50,3 %), mrzlica (48,6 %), zvišana telesna temperatura (42,8 %), navzea (35,6 %), gripi podobna bolezen (30,5 %) in bolečina na mestu injiciranja (27,7 %).
UNIQUE IDENTIFIER - HUMAN READABLE DATA PC 
EDINSTVENA OZNAKA - V BERLJIVI OBLIKI PC
Infections with wild-type HSV-1 have been associated with serious adverse effects, including multi-organ failure and death, if a foetus or neonate contracts the wild type herpes infection. 
Okužbe z divjim tipom HSV-1 so spremljali resni neželeni učinki, vključno z odpovedjo več organov in smrtjo, v primeru okužbe ploda ali novorojenčka z divjim tipom herpetične okužbe.
Talimogene laherparepvec is produced in Vero cells by recombinant DNA technology. 
Talimogen laherparepvek je pridobljen v celicah Vero s tehnologijo rekombinantne DNA.
In an in vivo study of intracerebral injection, talimogene laherparepvec was 10,000-fold less neurovirulent as compared to the wild-type HSV-1 dose that results in death 50% of the time in mice. 
V in vivo študiji intracerebralnega injiciranja je bil talimogen laherparepvek 10.000-krat manj nevrovirulenten kot odmerek divjega tipa HSV-1, ki pri miših v 50 % povzroči smrt.
• Prioritise injection of remaining lesions based on lesion size until maximum injection volume is reached. 
• Preostale spremembe razvrstite po pomembnosti glede na njihovo velikost, dokler ni dosežena največja količina za injiciranje.
Adequate and well controlled studies with talimogene laherparepvec have not been conducted in pregnant women. 
Pri nosečnicah niso izvedli ustreznih in dobro kontroliranih študij s talimogenom laherparepvekom.
• Pain in ear, throat, abdomen, groin, back and underarm 
• bolečine v ušesu, žrelu, trebuhu, dimljah, hrbtu in pod pazduho,
Imlygic is used to treat adult patients with a type of skin cancer called melanoma that has spread in the skin or to the lymph nodes, when surgery is not an option. 
Zdravilo Imlygic uporabljamo za zdravljenje odraslih bolnikov s posebno vrsto kožnega raka, imenovanega melanom, ki se je razširil v kožo ali bezgavke, kadar operacija ni mogoča.
Although it is not known if Imlygic could be transmitted through sexual contact, it is known that wildtype HSV-1 can be transmitted through sexual contact. 
Ali se zdravilo Imlygic lahko prenaša s spolnim stikom, ni znano, znano pa je, da se s spolnim stikom lahko prenaša divji tip HSV-1.
• If storing thawed Imlygic in the original vial followed by a syringe: o the same temperature range should be maintained throughout the duration of storage until administration. 
• Če shranjujete odtajano zdravilo Imlygic v originalni viali in nato v injekcijski brizgi: o med časom shranjevanja do uporabe je treba vzdrževati enako temperaturno območje.
If Imlygic is used during pregnancy, or if the patient becomes pregnant while taking Imlygic, the patient should be apprised of the potential hazards to the foetus and/or neonate. 
Če je zdravilo Imlygic uporabljeno med nosečnostjo ali če bolnica zanosi med zdravljenjem z zdravilom Imlygic, jo je treba seznaniti z možno ogroženostjo ploda in/ali novorojenčka.
• Guide for healthcare professionals 
• Vodnik za zdravstvene delavce
Other medicines and Imlygic 
Druga zdravila in zdravilo Imlygic
§ American Joint Committee on Cancer (AJCC) staging 6th edition. 
§ 6. izdaja klasifikacije stadijev Ameriškega združenja za rak (AJCC - American Joint Committee on Cancer).
Healthcare professionals who are immunocompromised or pregnant should not administer Imlygic and should not come into direct contact with the Imlygic injection site(s) or body fluids of treated patients (see sections 4.3 and 4.4). 
Zdravstveni delavci, ki so imunokompromitirani, ali noseče zdravstvene delavke ne smejo dajati zdravila Imlygic in ne smejo priti v neposreden stik z mesti injiciranja zdravila Imlygic ali s telesnimi tekočinami zdravljenih bolnikov (glejte poglavji 4.3 in 4.4).
Log-rank p-value = 0.0511 Hazard Ratio [95% CI] = 0.79 [0.62, 1.00] 
Log-rank p-vrednost = 0,0511 Razmerje ogroženosti [95 % IZ] = 0,79 [0,62, 1,00]
Plasmacytoma at injection site* Blood and lymphatic system disorders Very common Oedema peripheral Common 
Občasni plazmacitom na mestu injiciranja* Bolezni krvi in limfatičnega sistema Zelo pogosti periferni edemi
1: GM-CSF (N = 86) Median (95% CI) 21.5 (17.4, 29.6) months 2: Talimogene Laherparepvec (N = 163) Median (95% CI) 41.1 (30.6, NE) months 
1: GM-CSF (N = 86) Mediana (95 % IZ) 21,5 (17,4, 29,6) mesecev 2: Talimogen laherparepvek (N = 163) Mediana (95 % IZ) 41,1 (30,6, NO) mesecev
Talimogene laherparepvec is an oncolytic immunotherapy that is derived from HSV-1. 
Talimogen laherparepvek je onkolitičen imunoterapevtik, izpeljan iz HSV-1.
Imlygic has not been studied in immunocompromised patients. 
Zdravilo Imlygic pri imunokompromitiranih bolnikih ni raziskano.
At doses up to 4 x 108 PFU/kg or 107 PFU/dose (60-fold over the highest proposed clinical dose), single or repeated doses of talimogene laherparepvec administered by SC, IV, or intratumoural injection were well tolerated in immunocompetent mice, rats, and dogs. 
V odmerkih do 4 x 108 PFU/kg ali 107 PFU/odmerek (60-krat več od največjega predlaganega kliničnega odmerka) v enkratnih ali ponavljajočih odmerkih talimogena laherparepveka, uporabljenega subkutano, intravensko ali v intratumorskih injekcijah so imunokompetentne miši, podgane in psi zdravilo dobro prenašali.
Nervous system disorders Very common Headache Common 
Bolezni živčevja Zelo pogosti glavobol
Accidental exposure 
Nenamerna izpostavljenost
This medicinal product contains 80 mg sorbitol (E420) per 4 mL dose. 
To zdravilo vsebuje 80 mg sorbitola (E420) na 4 ml odmerek.
Because talimogene laherparepvec is designed to enter and replicate in the tumour tissue, there could be a risk of foetal exposure to talimogene laherparepvec from tumour tissue that has crossed the placenta. 
Ker je talimogen laherparepvek zasnovan tako, da vstopi v tumorsko tkivo in se v njem razmnožuje, bi lahko obstajalo tveganje za izpostavljenost ploda talimogenu laherparepveku iz tumorskega tkiva, ki je prešlo skozi placento.
• 108 (100 million) PFU/mL - For all subsequent doses. 
• 108 (100 milijonov) PFU/ml - za vse nadaljnje odmerke.
Name and address of the manufacturers responsible for batch release Amgen Europe B.V. 
Ime in naslov izdelovalcev, odgovornih za sproščanje serij Amgen Europe B.V.
To submit the preliminary results from Study 20110266 (a phase 2, multicentre, randomised, open-label trial assessing the efficacy and safety of talimogene laherparepvec neoadjuvant treatment plus surgery vs surgery alone for resectable stage IIIB to IVM1a melanoma) 
Predložiti preliminarne rezultate iz študije 20110266 (multicentrične, randomizirane, odprte študije faze II za oceno učinkovitosti in varnosti neoadjuvantnega zdravljenja s talimogenom laherparepvekom skupaj s kirurškim posegom v primerjavi s samim kirurškim posegom pri bolnikih z operabilnim melanomom stopenj IIIB do IVM1a).
Lethal systemic viral infection was observed in up to 20% of nude mice (primarily deficient in T lymphocyte function) and 100% of SCID mice (devoid of both T and B lymphocytes). 
Sistemske virusne okužbe s smrtnim izidom so opažali pri do 20 % golih miši (primarno pomanjkanje delovanja limfocitov T) in pri 100 % miši SCID (ki so tako brez limfocitov T kot limfocitov B).
This medicine contains 80 mg sorbitol in each 4 mL dose. 
To zdravilo vsebuje 80 mg sorbitola v vsakem 4 ml odmerku.
As with other wild-type HSV-1 infections, a latent pool of talimogene laherparepvec DNA may persist in neuronal cell bodies innervating the injection sites; therefore, the occurrence of latent infection with talimogene laherparepvec cannot be excluded. 
Tako kot velja za druge okužbe z divjim tipom HSV-1, lahko ostane DNA talimogena laherparepveka latentno prisotna v telesih nevronskih celic, ki oživčujejo mesta injiciranj, zato pojava latentne okužbe s talimogenom laherparepvekom ni mogoče izključiti.
• After administration, change gloves prior to applying occlusive dressings to injected lesions. 
• Po injiciranju zdravila zamenjajte rokavice, preden namestite okluzivni povoj na spremembe, v katere ste injicirali.
Treatment interval 
Interval zdravljenja
• When removing the needle, withdraw it from the lesion slowly to avoid leakage or splash back of Imlygic at the insertion point. 
• Ko odstranjujete iglo, jo iz spremembe izvlecite počasi, da boste preprečili iztekanje zdravila Imlygic ali da bi to brizgnilo iz mesta vboda.